Heron Therapeutics Signals Profitable Growth After Strong Quarter

Heron Therapeutics Inc ((HRTX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Heron Therapeutics’ latest earnings call struck a cautiously upbeat tone, with management highlighting record revenue, expanding margins and a move into sustained profitability, even as oncology headwinds, pricing pressure and litigation risks tempered the outlook. Investors heard a clear message of commercial inflection in Acute Care and disciplined spending aimed at long‑term value.

Record Revenue and Profitability Beat Expectations

Heron reported full‑year 2025 net product sales of $154.9 million and adjusted EBITDA of $14.7 million, more than double the prior year and above guidance of $9 million to $13 million. Gross margin reached about 73%, underscoring tighter cost control and a more favorable mix of higher‑margin products.

Acute Care Franchise Accelerates Into Year-End

Acute Care net sales climbed to $16.3 million in the fourth quarter, up roughly 33% from $12.3 million in the third quarter. The franchise grew more than 57% year over year in the quarter, signaling meaningful traction heading into 2026 as hospitals and ambulatory centers increase adoption.

ZYNRELEF Delivers Growth and Reimbursement Tailwinds

ZYNRELEF generated fourth‑quarter net sales of $12.5 million, up from $9.3 million in the prior quarter and 48% higher year over year, reinforcing its role as the core Acute Care growth driver. Reimbursement visibility improved with a permanent J‑code and streamlined administration via the VAN rollout, while the prefilled syringe program advanced despite a multi‑year approval timeline.

APONVIE Adoption Ramps With Guideline Support

APONVIE posted Q4 net sales of $3.8 million, up 97% year over year, with demand units increasing about 101%, showing rapid uptake in postoperative nausea and vomiting prevention. Inclusion in the Fifth Consensus Guidelines and a permanent J‑code, combined with a dedicated hospital‑focused sales team, are expected to further accelerate hospital penetration.

Financing Removes Overhang and Bolsters Flexibility

Management highlighted a 2025 financing transaction that removed a capital‑structure overhang and strengthened the balance sheet. This improved financial position gives Heron room to step up targeted commercial investments, support launches and execute on growth initiatives without sacrificing overall profitability.

Operational Levers Sharpen Commercial Execution

Heron cited several operational initiatives as key enablers of recent momentum, including the CrossLink IGNITE incentive program that has now been extended into 2026. The completed VAN rollout, permanent reimbursement coding and guideline inclusion are all designed to reduce friction for hospitals and distributors and improve field execution.

Oncology Franchise Faces SUSTOL-Driven Headwinds

The Oncology franchise produced just over $105 million in 2025 revenue, a 7.8% decline versus 2024 that management mainly attributed to the planned wind‑down of SUSTOL through 2026. Fourth‑quarter Oncology net sales were $24.2 million, and this shrinking base creates a structural headwind that Acute Care growth must offset.

CINVANTI Navigates Competitive and Pricing Pressure

CINVANTI demand remains resilient, but the product is confronting intensified competition and expected price erosion, especially in clinics. Management anticipates unit and volume growth yet warns that pricing declines could largely offset these gains, leaving 2026 CINVANTI sales roughly flat absent new catalysts.

Near-Term EBITDA Impact From Higher Commercial Spend

The company plans to increase targeted commercial spending, including adding field capacity later in the year and prioritizing geographic expansion. While these moves may restrain near‑term EBITDA growth, Heron argues they should unlock faster revenue expansion and value creation over the next several years.

ZYNRELEF Prefilled Syringe Faces Multi-Year Timeline

Heron placed ZYNRELEF prefilled syringe registration batches on stability in the fourth quarter of 2025, kicking off a 12‑month testing period. With an additional four to six months of regulatory review expected, management now points to a mid‑ to late‑2027 approval window, extending the wait for this key formulation upgrade.

NOPAIN Act Benefits Delayed by Adoption Lag

Management acknowledged that provider awareness and implementation of the NOPAIN Act have progressed more slowly than hoped, delaying an anticipated reimbursement tailwind for ZYNRELEF. The company is ramping up education and support resources, but investors should expect a more gradual impact than initially envisioned.

Litigation Overhang Adds Legal and Market Risk

Heron addressed ongoing litigation related to CINVANTI, which is pending in federal court and remains an uncertainty for the franchise. While executives expressed confidence in their position and expect a decision before a key stay expiration, the ultimate outcome could influence both market dynamics and investor sentiment.

Guidance Points to Growth With Maintained Profitability

For 2026, Heron guided to net product sales of $173 million to $183 million and adjusted EBITDA of $10 million to $20 million, indicating continued top‑line growth but slightly lower mid‑point profitability as investments step up. Management reiterated its expectation to remain EBITDA positive and framed 2027 as a year when these investments should translate into stronger revenue and free‑cash‑flow generation.

Heron’s earnings call painted the picture of a company transitioning from turnaround to growth mode, with Acute Care products driving momentum and Oncology providing steady but pressured cash flows. Investors will be watching execution on commercial initiatives, the pace of NOPAIN and hospital uptake, and resolution of litigation as key swing factors for the stock in the coming years.